Phillips Medisize is excited to be exhibiting at the Drug Delivery to the Lungs (DDL) Conference December 10–12, 2025, in Edinburgh, Scotland.
We are proud to be presenting on a number of important topics, including:
- “Powder Deagglomeration in a Chaotic Flow: An Introduction to the O1 High Payload DPI Device” — Baudouin Géraud, Principal Physicist
- “Impact of Nitrocellulose-Free Foil on Dry Powder Inhaler Product Performance and Stability” — Bindu Harshini Cherukuri, Scientist
- “Addressing the Need for High Through-Put Testing of Breath Actuated Nebulizers” — Steph Bannister, Team Leader
- “Development of Cationic and Ionizable LNPs for Intranasal Delivery: The Influence of PEGylation on Formulation Characteristics” — Neil Forbes, Senior Scientist
- “Mitigating Colloidal Instability in Inhaled Spray Dried Lipid Nanoparticles Using an Amorphous Shell Former” — Mireia Puig-Sellart, Team Leader
Visit us at booth 169 to learn about our inhalation drug delivery device innovations and regional manufacturing site capabilities.
To set up some time with us at the conference in advance, fill out the contact us form and we will follow up with you.
If you have not yet signed up to attend DDL, feel free to use the following discount code at checkout: 10% off with code PMEDI10 Register for DDL now.
Our Inhalation CDMO Capabilities
The 2025 Vectura acquisition expanded our capabilities. Today, Phillips Medisize specializes in innovative inhaled drug development, leveraging more than 25 years of experience to help bring your medicines to market. Our combination of formulation science, device technology and inhaled development expertise has contributed to the success of 13 inhaled medicines launched by our partners and licensees.
Want to Meet Now?
To schedule a meeting with one of our subject-matter experts, please fill out the contact us form and we will follow up with you.